Otsuka, Ionis experimental ALS drug hits main goal in late-stage study

• Ulefnersen reduced markers of nerve cell damage and delayed disease progression in FUS-ALS patients, showing a favorable safety profile with mostly mild to moderate side effects
• FUS-ALS is a rare inherited form of ALS causing progressive muscle weakness that can leave patients unable to move, speak, swallow, or breathe independently, with no current approved treatments targeting its genetic cause
• Otsuka launched a global early access program allowing physicians to request ulefnersen for eligible FUS-ALS patients who cannot participate in clinical trials before potential regulatory approval

Otsuka and Ionis Report Positive Late-Stage Results for Experimental ALS Treatment

Otsuka Pharmaceutical and Ionis Pharmaceuticals announced on September 22 that their experimental drug ulefnersen successfully met the primary endpoint in a late-stage clinical trial for FUS-ALS, a rare inherited form of amyotrophic lateral sclerosis.

Key Trial Results:

Ulefnersen demonstrated improved function and survival compared to placebo in patients with FUS-ALS, a disease that damages nerve cells controlling movement. The drug also reduced biomarkers associated with nerve cell damage and delayed disease progression. The safety profile was favorable, with most side effects classified as mild or moderate.

Market and Regulatory Implications:

Currently, no approved treatments specifically target the genetic cause of FUS-ALS, positioning ulefnersen as a potential first-in-class therapy. Both companies plan to engage with the U.S. FDA and global health authorities to pursue accelerated approval pathways, which could expedite market entry.

Disease Background:

FUS-ALS causes progressive muscle weakness, potentially leaving patients unable to move, speak, swallow, or breathe independently. Ulefnersen is designed to reduce production of the FUS protein linked to the disease's pathology.

Expanded Access:

Separately, Otsuka launched a global early access program allowing eligible FUS-ALS patients who cannot participate in clinical trials to potentially receive ulefnersen through physician requests before formal approval.

Investment Outlook:

The positive results represent a significant development for both Otsuka and Ionis Pharmaceuticals in the rare disease treatment space, addressing a critical unmet medical need with no existing targeted therapies. The accelerated approval pathway discussion suggests potential near-term commercialization opportunities.